NewAmsterdam Pharma (NASDAQ:NAMSW) Shares Down 8.9% – Here’s Why

Shares of NewAmsterdam Pharma (NASDAQ:NAMSW) fell 8.9% during trading on Thursday . The company traded as low as $27.20 and last traded at $27.31. 16 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 2,005 shares. The stock had previously closed at $29.99.

NewAmsterdam Pharma Price Performance

The stock has a 50 day moving average of $21.99 and a 200 day moving average of $23.45.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NewAmsterdam Pharma stock. Aristeia Capital L.L.C. bought a new stake in NewAmsterdam Pharma (NASDAQ:NAMSW) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 15,708 shares of the company’s stock, valued at approximately $397,000.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon?like peptide?1 (GLP-1) receptor agonist currently in early clinical trials.